SK Biopharmaceuticals Co., Ltd.

KOSE:A326030 Stock Report

Market Cap: ₩8.1t

SK Biopharmaceuticals Valuation

Is A326030 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A326030 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A326030 (₩102100) is trading below our estimate of fair value (₩172586.96)

Significantly Below Fair Value: A326030 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A326030?

Key metric: As A326030 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for A326030. This is calculated by dividing A326030's market cap by their current earnings.
What is A326030's PE Ratio?
PE Ratio139.1x
Earnings₩57.38b
Market Cap₩8.11t

Price to Earnings Ratio vs Peers

How does A326030's PE Ratio compare to its peers?

The above table shows the PE ratio for A326030 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average34.4x
A000100 Yuhan
49.9x20.4%₩8.3t
A128940 Hanmi Pharm
21x12.4%₩3.4t
A237690 ST PharmLtd
52.7x33.5%₩1.7t
A069620 Daewoong Pharmaceutical
13.9x14.6%₩1.4t
A326030 SK Biopharmaceuticals
139.3x66.4%₩8.0t

Price-To-Earnings vs Peers: A326030 is expensive based on its Price-To-Earnings Ratio (139.3x) compared to the peer average (34.4x).

Price to Earnings Ratio vs Industry

How does A326030's PE Ratio compare vs other companies in the KR Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
A007370 Jin Yang Pharmaceutical
2.4xn/aUS$46.19m
No more companies available in this PE range
A326030 139.1xIndustry Avg. 12.5xNo. of Companies8PE01020304050+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: A326030 is expensive based on its Price-To-Earnings Ratio (139.3x) compared to the KR Pharmaceuticals industry average (12.5x).

Price to Earnings Ratio vs Fair Ratio

What is A326030's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A326030 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio139.1x
Fair PE Ratio55x

Price-To-Earnings vs Fair Ratio: A326030 is expensive based on its Price-To-Earnings Ratio (139.3x) compared to the estimated Fair Price-To-Earnings Ratio (54.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst A326030 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₩102,100.00
₩121,928.57
+19.4%
20.4%₩150,000.00₩57,000.00n/a14
Dec ’25₩103,400.00
₩122,000.00
+18.0%
19.2%₩150,000.00₩57,000.00n/a16
Nov ’25₩114,400.00
₩109,428.57
-4.3%
20.9%₩140,000.00₩57,000.00n/a14
Oct ’25₩104,000.00
₩108,500.00
+4.3%
21.1%₩140,000.00₩54,000.00n/a14
Sep ’25₩115,000.00
₩107,785.71
-6.3%
20.7%₩140,000.00₩54,000.00n/a14
Aug ’25₩87,100.00
₩107,437.50
+23.3%
20.1%₩130,000.00₩54,000.00n/a16
Jul ’25₩78,900.00
₩107,437.50
+36.2%
20.1%₩130,000.00₩54,000.00n/a16
Jun ’25₩85,400.00
₩106,400.00
+24.6%
21.1%₩130,000.00₩51,000.00n/a15
May ’25₩87,600.00
₩106,133.33
+21.2%
21.5%₩130,000.00₩51,000.00n/a15
Apr ’25₩92,000.00
₩103,400.00
+12.4%
21.6%₩130,000.00₩50,000.00n/a15
Mar ’25₩96,900.00
₩105,062.50
+8.4%
21.4%₩130,000.00₩50,000.00n/a16
Feb ’25₩90,000.00
₩105,062.50
+16.7%
21.4%₩130,000.00₩50,000.00n/a16
Jan ’25₩100,400.00
₩105,333.33
+4.9%
21.6%₩130,000.00₩54,000.00n/a15
Dec ’24₩85,300.00
₩105,333.33
+23.5%
21.6%₩130,000.00₩54,000.00₩103,400.0015
Nov ’24₩75,600.00
₩105,266.67
+39.2%
21.9%₩130,000.00₩54,000.00₩114,400.0015
Oct ’24₩86,200.00
₩106,785.71
+23.9%
20.2%₩130,000.00₩65,000.00₩104,000.0014
Sep ’24₩82,100.00
₩106,266.67
+29.4%
19.7%₩130,000.00₩65,000.00₩115,000.0015
Aug ’24₩90,000.00
₩96,714.29
+7.5%
13.3%₩110,000.00₩65,000.00₩87,100.0014
Jul ’24₩80,900.00
₩94,923.08
+17.3%
13.5%₩110,000.00₩65,000.00₩78,900.0013
Jun ’24₩74,700.00
₩95,285.71
+27.6%
13.1%₩110,000.00₩65,000.00₩85,400.0014
May ’24₩69,000.00
₩94,692.31
+37.2%
16.5%₩110,000.00₩51,000.00₩87,600.0013
Apr ’24₩63,300.00
₩94,692.31
+49.6%
16.5%₩110,000.00₩51,000.00₩92,000.0013
Mar ’24₩66,700.00
₩95,500.00
+43.2%
18.3%₩120,000.00₩51,000.00₩96,900.0012
Feb ’24₩71,600.00
₩95,916.67
+34.0%
18.4%₩120,000.00₩51,000.00₩90,000.0012
Jan ’24₩72,100.00
₩95,916.67
+33.0%
18.4%₩120,000.00₩51,000.00₩100,400.0012
Dec ’23₩72,700.00
₩95,916.67
+31.9%
18.4%₩120,000.00₩51,000.00₩85,300.0012

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 16:45
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

SK Biopharmaceuticals Co., Ltd. is covered by 21 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Dae Woong YooBookook Securities Co. Ltd
Seohyun LeeCitigroup Inc
Sunghwan KimCredit Suisse